1. Colbrunn DK, Jacks C, Curry SR, Gebregziabher M, et al.
   Outcomes of discordant HIV screening test results at a southern academic medical center.
   AIDS 2024.
   


2. Crowell TA, Ritz J, Zheng L, Naqvi A, et al.
   Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.
   AIDS 2024.
   


3. Filip I.
   Changing costs of pre-exposure prophylaxis may undermine efforts to curb HIV infection rates.
   AIDS 2024.
   


4. .
   Prevalence and incidence of stroke among people with HIV: Erratum.
   AIDS 2024;38:777.
   


5. De Cock KM, El-Sadr WM.
   Authors' response to comment on 'Invisible, but not absent'.
   AIDS 2024;38:774-775.
   


6. Amon JJ.
   To end AIDS, human rights must remain at the center of the HIV response.
   AIDS 2024;38:773-774.
   


7. Fresse A, Massy N, Fournier D, Pinel S, et al.
   Adverse drug reaction profile of third-generation smallpox vaccines used in France during the 2022 monkeypox epidemic.
   AIDS 2024;38:768-771.
   


8. Fraser D, Holt M, Ong JJ, Bourne C, et al.
   A proposal for a simplified measure of HIV preexposure prophylaxis prevention-effective adherence in self-report questionnaires.
   AIDS 2024;38:765-767.
   


9. Gonzalez-Scarano F, Napravnik S, Vance DE.
   Frailty and HIV-associated neurocognitive disorder are only modestly associated.
   AIDS 2024;38:757-759.
   


10. Goodreau SM, Wohlfeiler DA, Bertrand T.
    Bringing back condoms.
    AIDS 2024;38:761-763.
    


11. Wilkinson L, Grimsrud A.
    Enabling effective differentiated service delivery transitions for people on antiretroviral treatment.
    AIDS 2024;38:615-622.
    


12. Wohlfeiler MB, Weber RP, Brunet L, Siddiqui J, et al.
    Incident HIV-Associated Wasting/Low Weight is Associated with Nearly Doubled Mortality Risk in the Modern ART Era.
    AIDS Res Hum Retroviruses 2024.
    


13. Folgosi VA, Konminakis SV, Silva FDD, Leite Junior PD, et al.
    Evaluation of the New Multi-HTLV Serological Assay: Improvement for HTLV-2 Detection.
    AIDS Res Hum Retroviruses 2024;40:134-140.
    


14. Fajami Z, Akbarin MM, Rafatpanah H, Ramezani S, et al.
    Assessment of Bcl-xL, TAX, and HBZ Gene Expression in Adult T cell Leukemia/Lymphoma Patients.
    AIDS Res Hum Retroviruses 2024;40:141-147.
    


15. Landovitz RJ, Tao L, Yang J, de Boer M, et al.
    HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
    Clin Infect Dis 2024.
    


16. Minter DJ, Appa A, Chambers HF, Doernberg SB, et al.
    The positioning of ceftobiprole in the treatment of Staphylococcus aureus bacteremia.
    Clin Infect Dis 2024.
    


17. Ngo HX, Xu AY, Velasquez GE, Zhang N, et al.
    Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
    Clin Infect Dis 2024.
    


18. Dorward J, Sookrajh Y, Lessells R, Bulo E, et al.
    Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr 2024;95:e8-e11.
    


19. Kabami J, Koss CA, Sunday H, Biira E, et al.
    Randomized Trial of Dynamic Choice HIV Prevention at Antenatal and Postnatal Care Clinics in Rural Uganda and Kenya.
    J Acquir Immune Defic Syndr 2024;95:447-455.
    


20. Youngui BT, Atwine D, Otai D, Vasiliu A, et al.
    Integration of HIV Testing in a Community Intervention for Tuberculosis Screening Among Household Contacts of Patients with Tuberculosis in Cameroon and Uganda.
    J Acquir Immune Defic Syndr 2024;95:431-438.
    


21. Shade SB, Gutin SA, Agnew E, Grignon JS, et al.
    Cost Analysis of Short Messaging Service and Peer Navigator Interventions for Linking and Retaining Adults Recently Diagnosed With HIV in Care in South Africa.
    J Acquir Immune Defic Syndr 2024;95:417-423.
    


22. Fu W, McClymont E, Av-Gay G, Dorling M, et al.
    Retrospective Cohort Study on the Impact of the COVID-19 Pandemic on Pregnancy Outcomes for Women Living With HIV in British Columbia.
    J Acquir Immune Defic Syndr 2024;95:411-416.
    


23. Moawad MHED, Mohamed Shalaby MM, Hamouda E, Mahfouz A, et al.
    Risk of Stroke Among HIV Patients: A Systematic Review and Meta-analysis of Global Studies and Associated Comorbidities.
    J Acquir Immune Defic Syndr 2024;95:399-410.
    


24. Madlala HP, Myer L, Geffen H, Rusch J, et al.
    Inflammatory markers in pregnancy are associated with postpartum weight in South African women living with HIV on antiretroviral therapy.
    J Acquir Immune Defic Syndr 2024.
    


25. Nunez I, Ceballos-Liceaga SE, Torre A, Garcia-Rodriguez G, et al.
    Clinical features and outcomes of mpox in people with and without HIV: a national comparative study.
    J Acquir Immune Defic Syndr 2024.
    


26. Weiser J, Tie Y, Crim SM, Riedel DJ, et al.
    Do HIV Care Outcomes Differ by Provider Type?
    J Acquir Immune Defic Syndr 2024.
    


27. Elizaldi SR, Hawes CE, Verma A, Shaan Lakshmanappa Y, et al.
    Chronic SIV-induced neuroinflammation disrupts CCR7+CD4+ T cell immunosurveillance in the rhesus macaque brain.
    J Clin Invest 2024.
    


28. Gruner E, Grossegesse M, Stern D, Ober V, et al.
    Mpox-specific immune responses elicited by vaccination or infection in people living with HIV.
    J Infect Dis 2024.
    


29. Burdorf R, Zhou S, Amon C, Long N, et al.
    Impact Of Low-Frequency HIV-1 Drug Resistance Mutations On Antiretroviral Therapy Outcomes.
    J Infect Dis 2024.
    


30. Corma-Gomez A, Cabello A, Orviz E, Morante-Ruiz M, et al.
    Long or complicated mpox in patients with uncontrolled HIV infection.
    J Med Virol 2024;96:e29511.
    


31. Kankasa C, Mennecier A, Sakana BLD, Moles JP, et al.
    Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.
    Lancet 2024.
    


32. Mutale W, Herce ME.
    Closing the gap in paediatric HIV infections: how available tools and technology can accelerate progress towards ending AIDS by 2030.
    Lancet 2024.
    


33. .
    Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden
    Lancet 2024.
    


34. Cohen J.
    'I'm not Tony': Anthony Fauci's heir vows new direction at NIAID.
    Science 2024;383:1168-1169.
    


35. Dyer O.
    Surge in anti-gay laws in Africa imperil progress on HIV/AIDS, experts say.
    BMJ 2024;384:q599.
    

Display articles in

• Abstract format
• Medline format